Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia ...

A groundbreaking development in hypertension treatment has emerged from the University of South Wales, offering new hope for the 1.28 billion adults worldwide affected by high blood pressure.

Patients aged 65 years and older who use acetaminophen demonstrate greater risks for serious complications, including ...

While high blood pressure can contribute to renovascular disease, having renal (kidney) problems can also increase blood ...

Elevated blood pressure is the most important risk factor for cardiovascular disease. Numerous clinical practice guidelines for blood pressure coexist, emanating from European,1,2 North American,3 ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Hypertension in pregnancy increases the likelihood of postpartum hypertension. Know the risk factors to start managing ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...